All In MedTech

Device Trial Radar · NCT01501617

Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia

The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial

Last checked: Nov 19, 2026Latest source record: Jan 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

56

Actual

Start

Dec 2011

Primary completion

Jun 2012

Study completion Dec 2012

Sponsor

Lead sponsor
HistogenNot on our public-company list
Sponsor type
Industry
Collaborators
Gleneagles CRC Pte Ltd.
First posted
Dec 29, 2011

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 21 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy in relation to dosing in the administration of Hair Stimulating Complex (HSC) in healthy men. HSC will be injected intradermally in the scalps of men with male pattern baldness (i.e. androgenetic alopecia).

Conditions

  • Androgenetic Alopecia

Interventions

  • Hair Stimulating Complex (HSC)Biological

    Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.

  • Dulbecco's Modified Eagle Medium, DMEMDevice

    Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Systemic safety measures will be assessed by measuring vital signs, adverse experiences, laboratory tests (hematology, clinical chemistry and urinalysis)and immunological response (anti-drug antibodies)Time frame: Clinically significant change from screening visit to Week 12
  2. Non-vellus hair countsTime frame: Change from Baseline to week 12 in treatment areas

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Medical City

    Pasig, Manila, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.